Iron Overload Disease Causes Rapid Growth Of Deadly Vibrio Vulnificus Bacteria
Every summer, there are reports linking a bacterium called Vibrio vulnificus
to people getting sick or dying. The bacteria are found in warm
saltwater and problems occur after eating raw tainted shellfish or when
an open wound comes in contact with seawater.
People with a weakened immune system, chronic liver disease or iron overload disease are most at risk for severe illness. Vibrio vulnificus infections in high-risk individuals are fatal 50 percent of the time.
Now, researchers at UCLA have figured out why those with iron
overload disease are so vulnerable. People with the common genetic iron
overload disease called hereditary hemochromatosis have a deficiency of
the iron-regulating hormone hepcidin and thus develop excess iron in
their blood and tissue, providing prime growth conditions for Vibrio
vulnificus.
A microscopic look at Vibrio vulnificus bacteria swimming around. Credit: Paul Gulig/University of Florida
The study also found that minihepcidin, a medicinal form of the
hormone hepcidin that lowers iron levels in blood, could cure the
infection by restricting bacterial growth.
"This is the first time that the association of hepcidin deficiency
and susceptibility to Vibrio vulnificus infection was tested," said
senior author Dr. Yonca Bulut, a clinical professor of pediatrics at
Mattel Children's Hospital at UCLA and a researcher with the UCLA
Children's Discovery and Innovation Institute. "The dramatic
effectiveness of the new treatment, even after the infection was
established, was impressive."
To conduct the study, researchers compared the fatality of Vibrio
vulnificus infection in healthy mice with mice that lacked hepcidin,
modeling human hereditary hemochromatosis. The results showed that the
infection was much more lethal in hepcidin-deficient mice because they
could not decrease iron levels in the blood in response to infection, a
process mediated by hepcidin in healthy mice.
Giving minihepcidin to susceptible hepcidin-deficient mice to lower
the amount of iron in the blood prevented infection if the hormone was
given before the Vibrio vulnificus was introduced. Additionally, mice
given minihepcidin three hours after the bacterium was introduced were
cured of any infection.
Hereditary hemochromatosis is a genetic disease that causes the body
to absorb and store too much iron. It affects as many as 1 in every 200
people in the United States. Since it can take decades for the body to
store damaging levels of iron, many people may not be aware that they
have the disease until signs of the condition begin to appear later in
life.
The co-directors of the UCLA Center for Iron Disorders, Dr. Tomas
Ganz, a professor of medicine and pathology at the David Geffen School
of Medicine at UCLA, and Elizabeta Nemeth, a professor of medicine at
UCLA, led the invention of minihepcidins at UCLA. Minihepcidins are
being developed for treatment of iron-overload disorders, such as
hereditary hemochromatosis and Cooley's anemia. The use of minihepcidin
to treat potentially lethal infections is a possible new application.
"We found that hepcidin is required for resistance to a Vibrio
vulnificus infection," said the study's lead author Joao Arezes, a
visiting graduate student from the University of Porto in Portugal. "The
development of the treatment tested in mouse models could reduce the
high mortality rate of this disease."
The next stage of research is to understand why Vibrio vulnificus
bacteria become so lethal when iron levels are high, and to learn which
other microbes respond similarly to excess iron.
The research was conducted at the UCLA Center for Iron Disorders. The
early findings were reported online Jan. 14 in the journal Cell Host
and Microbe. Other study authors were Grace Jung, Victoria Gabayan,
Erika Valore, Piotr Ruchala, Ganz and Nemeth, all of UCLA, and Paul
Gulig of the University of Florida. The study was funded by the UCLA
Today's and Tomorrow's Children Fund, the UCLA Stein/Oppenheimer
Endowment Award, the UCLA Children's Discovery and Innovation Institute
and the National Institutes of Health (grant R01 DK090554).
Comments
Post a Comment